health i ,ĩĩi !i i i ~ l and molecular medicine work together Asthma Is recognized as the most common treatable chronic disease of the lung, afflicting over 100 million people of all age groups yet, despite therapeutic advances, there has been U~ie impact on the rising morbidity and mortality from the disease. This article discusses ways in which molecular medicine can Inform public ~lth policy and clinical practice in the management of asthma, it focuses on the recognition that asthma Is an Inflammato~ disorder, and that the public health burden of the disease can be reduced by Identifying environmental factors that may trigger asthma in genetically susceptible individuals.
William Osier first alluded to the importance of airway inflammation in asthma in 1892, yet it has taken us over 100 years to gain an insight into the pathogenesis of asthma, primarily because of the difficulty in obtaining access to 'airway tissue' in living patients. With the introduction of fibre-optic bronchoscopy and also advances in molecular medicine, the past decade has seen a major change in how asthma is perceived: as a disease of airway inflammation rather than solely in terms of disordered smooth muscle function. The disease process is now accepted to involve the action of several types of immune response and a number of different cell types, including eosinophils, mast cells and T cells, acting in an orchestrated fashion. This knowledge of the molecular mechanisms in asthma has changed the emphasis of the clinical management of asthma towards the recognition of the central role of allergen-provoked inflammation, and has minored the development of more selective and more potent drugs specific for the mediators of inflammation. This shift in emphasis has public health implications for the prevention of asthma: these will be discussed in this short article.
Allergic airway inflammation in asthma
The clinical expression of asthma spans a wide spectrum, from mild seasonal symptoms to severe, intractable and debilitating disease. There has been an explosion in knowledge over the past decade in the understanding of the complex interactions of cytokines and their effects on the differentiation, maturation and activation of different cell types and subsets, Modem molecular techniques, such as immunohistochemistry, bz situ hybridization and PCR, have been applied to the examination of biopsies of bronchial tissue and cells obtained by washing out sections of the airways (bronchial lavage) of mild to moderate asthmatics. These studies have led to the recognition that there is a characteristic repertoire of cytokines produced by the Th2 subset of CD4 ÷ helper T cells in asthma. From this understanding, a cohesive explanation of the role of cytokines in asthma can be derived (Fig. I) .
Acute airway inflammation
The airways of asthmatic patients respond to inhaled allergen by producing an acute phase of bronchoconstfiction (early asthmatic response, EAR) followed by ft~rther bronchoconstdctkm i~a~e asthmatic response, LAR) tFig. 2). After recoveu there is an increase in acquired bronchial hyperresponsiveness ~BHR)to agents s~cl~ as mefimcho~ine and histamine: this can persist ~br se',eral days ~ffter fl~e resohlfion of the LAR. In the short term, this "acute rnodd' of allergen provocation has helped to explain why some of the currendy used drugs are effective for the management of asthma. Both nedocromil sodium and sodium cromoglycate inhib;t the EAR, LAR and BHR by inhibiting ~t~e rdease of mast-cell-derived mediators Isce Fi~ 2,. (7or~icosteroids reduce the LAR. probabb by inhibiting the c}~okine-medta~ed upregulafion of adhe@m molecule:, on the puhnoaar}: ~:,icro',a~<ularare that is responsible ik~r ~eukoc}~c recruim~em m ~he airaa} s. The~ also reduce the secretion of cytokines from ma.q cells and T cd~s. These are suppressive erects ~hat are ~hought to result from the conicosteroid binding to a cytoplasmic receptor, formation of a complex that binds to specific sites on DNA. and activation or repression of 
IL-5
Allergen "~'~~-~------TNFo(~. / / / IL.5 Figure 1 . The role of cytokines in inflammatory responses in asthma. In asthma, cytokines are produced as a result of the upregutation of the interleukin 4 (IL-4) gene cluster ILL-3, IL-4, IL-5, IL-6, IL-9, IL-13 and granulocyte-macrophage colony-stimulating factor (GM-CSF)] in leukocytes in response to allergen provocation. These cytokines are of fundamental importance to the initiation and maintenance of the allergic inflammatory response. The inflammatory events seen in asthma, including T-cell activation and release of pro.inflammatory mediators by mast cells, occurs after the switching of the isotype of antibody produced by B cells to immunoglobulin E (IgE), which is mediated/regulated by the cytokines IL-4 and IL-13 produced by T helper (Th) cells and follows the presentation of allergen to B and T cells by dendritic cells and macrophages. The Th2 T-cell subset matures and expands under the influence of IL-4 produced by both Th cells and mast cells. IL-3, IL-5 and GM-CSF induce the maturation and activation of eosinophils and basophils, resulting in eosinophil recruitment to the airways from pulmonary vasculature; and IL-6 and IL-9 are important in mast-cell maturation and upregulation of IgE secretion from B cells. The production of other cytokines that would suppress this characteristic response in asthma is reduced; these 'anti-asthmatic' cytokines are: interferon ',/(IFN-% produced by Thl cells; and IL-12, produced by monocytes and macrophages. The bronchial epithelium (IL-6, IL-8, GM-CSF) and fibroblasts [IL-8, GM-CSF, stem-cell factor (SCF)] are also important cytokine producers, and these cells have a role in severe asthma, where continuous T-cell activation and leukocyte recruitment persist even after the stimulus of attergen provocation has ceased (not shown Figure 2 , The airways of asthmatic patients respond to inhaled allergen (measured by determining the forced expiratory volume in 1 sec, FEV,) by producing an ~.eute phase of bronchoconslrtetlorl [early asthmatic response, EAR), primarily caused by immunoglobulin E (igE).medialed release of the masl-cell-denved autocoi(JS leukotrlene Ca (LTC,), prostaglandin O, (PGD~: and its metabolite 9~,,1 fI~.PGF~, not sllown) and histamine, in descending order of potency. After recovery over 1 h, this iS foIIowod by further bronchoconstriction (late astigmatic response, LAR) starting at around 2-4 h and reaching a maximum at 6-8 h, followed by recovery, U~ually over 24 h, The LAR occurs in association with an influx of neutrophtls and eosinophils into the airways, These events are followed by an increase in a~ulred btonehto, I hyperresl:)onslveness (BHR) to agents such as methacholine and histamine; this can persist for several days after the resolution of the LAR. specific genes coding for cytokines, Similar transcription-factormediated downregulation of both cytokine production and proinflammatory pathways is likely to account for the efficacy of most anti-asthma drags in current use.
Chronic airway inflammation and repair
Statistics of the 'cost of illness' for adult asthma, according to disease severity, reveal a disproportionate use of medical resources by patients with severe disease. In North America, 10% of asthmatics have severe asthma, yet this minority accounts for over 54% of the total resources allocated to the control and management of the disease. Similar data from other countries confinn that severe asthmatics are more likely to consult asthma specialists, use emergency room services and require hospitalization. On the grounds of public health costs alone, there is a clear case for focusing scientific research on this group of asthmatics, particularly in identifying factors that contribute to the chronicity and severity of the disease. While it is recognized that airway inflammation underlies the pathophysiology of asthma, its relationship to disease severity is less clear. Although I 194 'biomarkers', such as the presence of eosinophils ill the sputum and a persistent blood eosinophilia, relate to disease severity, these measures are too v,u~able to provide clinically useful markers to predict the !~vel of airway inflammation. Furthermore, the observation that patients with asthma have persistent airway inflammation, even in the absence of provoking allergens, suggests complex cellular and mediator mechanisms in maintaining the inflammatory response beyond allergen provocation. It is the continued allergen-specific production of immunoglobulin E (igE) in severe disease that provides the rationale for allergen avoidance in asthma. Recent epidemiological studies have li~ked the level of total serum lgE to disease progression, although there have been few long-term studies on airway inflammation and long-term prognosis. The evidence that does exist suggests that severe and poorly controlled asthma progresses to an increasing, irreversible condition. Severe and prolonged inflammation in most tissues is almost always accompanied by tissue remodelling, and the airways are no exception, although the mechanisms involved and their contribution to the overall pathophysiology of severe and chronic asthma have not been fully evaluated.
It follmvs that the severity and chronicitv of asfim~a res~]t from tl3e dysregulation of cytokme ncm'orks, ~eadmg to persistent inflammation, which becomes refractory to treatment, in struc~.trally altered airv~a~ s. The responsibility for disease progressio~ does no~ lie with any singie cellular element but embraces T and B cells, mas~ cells, eosim~phils, endothelial cells, epithelial cells and myofibrobhsts acting cooperatively with each other and with formed elements of the airways, including smooth muscle and nerves, leading to the variable phenotype that is characteristic of severe disease. "1"his provides an ~ntegrated view of asthma as a chronic disease of ongoing inflmnmation and repair.
Nitric oxide and asthma = a new noudnvasive test
One of the persisting difficulties in the management of moderate to severe asthma is the inability to monitor ah'way inflammation wiflmut the use of invasive investigations. Recently, it has been rec-ogaized that nimc oxide (NO) is impor~an~ ia asthma a>~ a ~ a3c~di!a~:: neurotransmi~ter and inf~ammamr~ mediator NO is ge~e~:~ed from i.-arginme by ~he enzyme NO s~mhase, which ca~ e-:ist in cons~ituti',e and inducible isoforms ~cNOS and iNOS. respectively }. Our group has recently shmvn, using immunological ~echniques, ~hat tNOS is pre,,ent in lage amounts in the bronchial epithelium of mild asthmatics. but only rarely in people unaffected by asthma. Consistent with the hypothesis that there is an increase in NO generation associated with airway inflammation is the increase m NO detected in exhaled air in people with symptomatic asthma or rhinitis. This production of NO by human airway epithdial cells has been shown to be inhibited by the addition of corticosteroids to cells in vitro. Further evidence indicates that iNOS is downreguhted {possibly by blocking NF-gB} in those people with asthma that responds to corticosteroids, and this response to the corticosteroids is associated with a reduction m NO Early allergen ~,~osure Virus infections Air pollution / Cigarette smoke + Viruses Allergens
Asthma symptoms
Environmental factors, particularly inhaled allergens such as house dust mite (HI)M), pollen and fungal spores, are impo~ant in the development of asthma. Studies have shown a link between the prevalence of asthma and the long-term exposure to allergen: and if the exposure to allergens is reduced, the symptoms o7 asthma tend to improve. These observatio,~s slrongly suggest that allergens induce the onset of asthma by stimulating a chronic, allergic inflammation in the airways. Identifying ways to reduce allergen exposure, or modulate the factors that may reduce 'sensitization', are important research priorities with implications for public health. One factor known to influence airway sensitization is the quality of air we breathe, h is recognized that air pollutants such as ozone, nitrogen dioxide and sulphur dioxide can trigger aslhma e×acerbafio~s, b~lt the in~e~'action of susceptible people with environmental allergens may be more important than the control of the gases in flleir environment, Studies in which l~ople have been kept in con|rolled chambers have shown that ex~sure to cerlain pollutants, or a comoination of them, can enhance the reslmnse of the airway to allergens, Thus, the environ~ meat in which susceptible people live and work could provide im!~r~ tant targets lbr the prevention of asthma; fu~er investigations will be needed before such approaches can be implemented effectively,
Coexistent virus infection has also been implicated a~ a thctor that affects the inflammatory events in individuals with asthma, There is evidence that first.born children are at greater risk of developing asthma than siblings that follow. Although the mechanisms are unknown, one explanation is that younger children of the family are in some way protected by early exposure to infectious agents, such as the measles virus. Early in life, viruses aM other infections may pro* tect the children rather than make them more liable to illness. In later childhood, viruses clearly have the capacity to exacerbate asthma. Using PeR, we have recently shown that common respiratory viruses, particularly rhinovirus and coronavirus, are associated with exacerbations of asthma in children, and hospital admissions for asthma in adults. However, although viruses are important in short-term exacerbations of asthma in children, continued exposure to allergens remaina the main drive behind the persistence of asthma symptoms into adulthood in susceptible individuals.
Glossary
Atopy -The genetic predisposition for mounting an immunoglobu-Un (predominantly IgE) response to common allergens. It is associated with increased levels of IgE in the circulation and tissues and is the major risk factor for developing asthma.
Bronchial hyperresponsiveness -Describes airways that narrow too readily or too much in response to a provoking stimulus. In asthmatic patients, the airways can be hyperresponsive to many different stimuli. The airways of people without asthma are not hyperresponsive.
Nuclear factor KB (NF-KB) -A transcription factor, involved in the upregulation of adhesion molecules that are important in leukocyte recruitment from the peripheral circulation. By binding to specific promoter sites on genes coding for adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1), NF-KB can activate or suppress the target genes.
Stem, cell factor (SCF) -A growth factor necessary for mast cells; produced by fibroblasts. Also known as c-Kit ligand or Steel factor, in exhaled air. For NO to be present in the exhaled air in people with severe asthma, it is likely that the bronchial epithelium itself is a major source of NO. The ability to monitor the production of NO in exhaled air could provide a novel non-invasive surrogate marker of disease activity and response to treatment -an especially usefid tool for the identification of severe airway inflammation.
Atopy and asthma
Although asthma and the related condition atopy run in families. the relationship between the expression of these two diseases is not simple. If an individual has both atopy and asthma, this increases the risk by as much as threefold that the individual's siblings or descendants will have asthma; the presence of atopy alone d~s not influence the risk of asthma to related family members. Thus, although asthma and atopy may b¢ inherited independently, the presence of asthma and atopy, or atopic conditions such as eczema, in an individual increases the risk of asthma in his or her relatives. Atopy is clearly not synonymous with asthma; -40% of the population are atopic yet, depending on age, the prevalence of asthma is lower (-10-15%) in Western countries, These observations may be explained by the likeliht~l that multiple genes are involved in asthma and atopy; it is also likely that environmental f,~ctors are key to the triggering of an allergic response in genetically susceptible individuals. Rather tentative evidence that local (within the airway itself) or environmental factors arc important to the development of asthma in people who ,are genetically susceptible is the observation that asthma may be transmitted to recipients who are not otherwise susceptible, by lung transplantation from donors with asthma.
Genetic and environmental factors
It is beconfing increasingly clear that genetic and environmental factors (Box 1) are important in the aetiology of asthma. Genetic epidemiological studies have suggested at least two major genes that influence the 'asthmatic phenotype' that results from an inherited susceptibility. A group at the Institute of Molecular Medicine (Oxford, i 196 UK) have suggested that asthma is inherited as an autosomaldominant trait, and the gene is located on the human chromosome 1 l: however, other investigators have failed to confirm this association. A less controversial finding is that the interleukin 4 (IL-4) gene cluster involved in allergic disease (Box l) is coded on human chromosome 5; at least two studies have reported strong linkage between asthma susceptibility and this chromosome. Our own studies have demonstrated an allelic association between two polymorphisms of the gene for the cytokine IL-9 and the concentration of serum IgE (measured in log international units ml-~). Taken together, these observations strongly suggest a genetic effect on the level of expression of the IL-4 gene cluster in T cells, mast cells and eosinophils. The development of microsatellite markers at defined points across the whole of the human genome will provide a powerful tool to screen for genes linked to chronic diseases such a~ asthma and atopy by appaying the principles of reverse or positional cloning; this will have implications for the response of public health to the screening, diagnosis and management of people with asthma. Focusing on the role of genetic and environmental factors in allergen-provoked airway inflammation will provide new insights into how the disease could be prevented, rather than how it can be treated using drugs alone.
Early exposure to allergens
Factors in early life, such as atopy, low birthweight and maternal smoking during pregnancy, are known to increase the frequency and severity of 'wheezing illnesses' (or asthma) in infancy, yet less is known about the factors that predict wheezing in adolescence. This suggests that, whilst the symptoms of asthma in adults are caused by airway inflammation, wheezing symptoms ill infancy are related to the size of the airways in utero and during the first year of life, which, in turn, are susceptible to environmental in,,ults. The MRC Enviromnenta! Epidemiology Unit (Southampton, LIK)has shown that obstructive hmg disease, such as asthlna and allergies, in late adulthood is associated with disproportionate growtll as a loetus. An enlarged head size at birth in relation to body size is strongly associated with elevated serum IgE in adulthood, and it is possible that Ihis is related to thymic maturation. The size of the brain, and consequently the head circumference, is ~lated to the growth of the thymus gland, In some foetuses, undernutrition results in growth retardation and, as a result, a 'brain-sparing' reflex redistributes blood and nutrients to the brain at the expense of the trunk and limbs, including the thymus gland. Animal studies indicate that this would alter the Thl/Th2 lymphocyte population in the thymus, resulting in Th2 dominance and an immune response characteristic of that in asthma and allergy. Furthermore, T cells can be isolated from the foetal blood in the umbilical cord of babies born to parents who are atopic; if these cells are stimulated in vim~ with a specific allergen, they show impaired production of the 'allergy-suppressing' cytokine interferon ',/(IFN-',/) and enhanced IL-4 production. These observations suggest that the Th2 response to alle~ens that is characteristic of asthma might already be programmed b~ utero, and has given rise to the concept of 'foetal programming', whereby lung development in foetal and early life determines the expression of respiratory illness (including asthma and chronic bronchitis) and allergy in adulthood. Exposure to house dust mite (HDM) allergen in the first year of life has also been shown to determine whether or not an an atopic child will develop asthma, measured at the age of I 1. The age of onset of the first episode of wheezing in these children also correlates with the quantity of HDM exposure at the age of one year.
QuestJeas arising molecular mediciae @ Why do patients with even the rnildest forms of asthma stit| have e~dence of airway infianunafion? Wilt the prevemion of this inflanm~afion lead to ~provement in prognosis? o How important is the bronchial epithelium in maintaining fir,gay inflammNon? What significance could this have for ffeai.m~m. ¢ ¢ If viruses have the potential to protect against childhood wheezing illnesses, could the vaccination of children against common childhood hffeefions in developed countries account for the rising prevalence of asthma?
o Is the mixture of air pollutants in the air we breathe likely to be more toxic than than any single polluta~t'?
Using risk factors to prevent asthma
When the genetic, environmental and "early life' risk factors are better understood, it should be possible to identiI:v individuals at risk of asthma and, perhaps througll dietary regulation and allergen avoidance, asthma might be prevented in those most at risk. At least one study has already attempted to prevent the development of asthma. The early avoidance of dietary allergens {cows' milk and eggs) and measures to reduce ItDM exposure have been applied to babies born to atopic mothers in a study on the Isle of Wigh~ (UK). These seemingly simple measures resulted in a marked redactio:~ in wheezing, eczema, food intolerance, rhinitis and skin-test responses to common allergens measured at two years of age. Other studies have shown that public health measures can p|~vent asthma in ~he general population, including adults. Two of the most quoted s:udies have been carried out in Bmveiona (Spain) and Papua New Guir~ea; epidemics of asthma had been recorded in both places, and further outbreaks were prevented by reducing the exposure of the general popt|iation to soya bean dust {Spain) and HDM allergens {Papua New Guinea). A preventive strategy such as this could be applied to patients with mild to moderately severe asthma in developed countries, although it might be less useful in patients with severe asthma, who are the major public health burden.
Guidelines
Public health professionals often comment, with reference to asthma, that there is little value in developing effective therapies if they are not used. Current evidence shows that there are problems of underdiagnosis and, even if the correct diagnosis of asthma is made, many patients receive insufficient prophylactic therapy. Consequently, the past tenffears have seen the increasing use of national and international g~delines aimed at identifying and recommending 'the ideal multidisciplinary treatment of asthma'. Typical guidelines include: the education of patients and health professionals; advice on plans for self management by patients; and logical step-by-step drug treatment plans that emphasize early treatment with anti-inflammatory agents, particularly corticosteroids. Evidence from the USA, Europe and Australia suggests that such approaches may reduce hospital admissions for asthma, and improve compliance, inhaler techniques and symptom control.
The most recent, and perhaps most ambitious, initiative has been the Global Initiative for Asthma (GINA, 1995) , a joint US National !nstitutes of Heahh {NiH~ and WorHd Heahh O~ganization (Wi~Oi project. Under the aegis of GINA, an intema~ioa:d paae~ of e',perv, has idemif~ed priorities m the tream~em of asthma and suggested measures to implement them. With an emphasis on recognizing the importance of airway inflammation and improving patient_ and health-professional education, the tong-term goa~ is to form a consensus, that is common to countries across the world, on how the disease should be treated.
These guidelines assume that the degree of inflammation is mirrored by the severity of symptoms. The observation that the airways of asthmatics with only intermittent or mild symptoms are inflamed raises the question as to whether all asthmatics should be treated with anti-inflammatory agents, irrespective of the clinical severity. To assess whether such early intervention can affect the progression of intermittent asthma to a more severe or chronic condition requires longterm studies of the effects of treatment: these studies will also require careful monitoring of the side effects from the therapy. Whether national and international guiddines will have any lasting effect on the morbidity and mortality of asthma remains to be proven.
Prospects for the future
Our knowledge of the underlying mechanisms of asthma has been revolutionized by advances in molecular medicine coupled with studies of the environmental and genetic factors that affect asthma: these have successfully crossed the boundaries between basic and clinical science. We are now more confident that the application of the most recent tools of molecular and cellular biology will over me next decade, produce new insights into asthma apd provide strategies for public health, directed primarily towards prevention in the face of the rising prevalence of the disease.
